Skip to main content

Table 3 Baseline variables predictive of WPAI:SHP subscales at 6 and 12 months in 1747 RA patients

From: Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients

Predictor Odds ratio (95% CI)
 Outcome: absenteeism
  Fatigue 1.23 (1.02 to 1.49)
  Age (years) 1.20 (1.00 to 1.44)
  CRP 0.82 (0.68 to 0.98)
  % work time missed due to RA (> 0 vs 0) 4.75 (3.35 to 6.75)
  Visit 12 months vs 6 months 1.10 (0.83 to 1.46)
Predictor Standardized beta-coefficient (β) (95% CI)
 Outcome: presenteeism
  Fatigue 3.44 (2.17 to 4.71)
  Age (years) 1.44 (0.26 to 2.63)
  % impairment while working due to RA 9.36 (7.96 to 10.76)
  % impairment at 12 months vs % impairment at 6 months −1.98 (−3.39 to −0.58)
  Visit 12 months vs 6 months −1.16 (−2.57 to 0.24)
 Outcome: Work productivity loss
  Fatigue 4.16 (2.47 to 5.85)
  % overall work impairment due to RA 9.43 (7.74 to 11.12)
  Visit 12 months vs 6 months −0.60 (−2.64 to 1.44)
 Outcome: Activity impairment
  Fatigue 1.52 (0.79 to 2.26)
  Male vs female −1.83 (−3.33 to −0.33)
  Age (years) 3.25 (2.61 to 3.90)
  % activity impairment due to RA 9.41 (8.59 to 10.23)
  % activity impairment at 12 months vs % activity impairment at 6 months −1.92 (−2.67 to −1.18)
  Anxiety/depression Some vs none 2.80 (1.40 to 4.20)
Extreme vs none 5.81 (2.82 to 8.79)
  Visit 12 months vs 6 months −2.36 (−3.10 to −1.61)
  1. CI, confidence interval; CRP, C-reactive protein; RA, rheumatoid arthritis; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems